Zeleris Now Licenced To Treat Mycoplasma Bovis
8 months ago 
648 views
Ceva Animal Health has extended the licence for Zeleris which is now indicated for the treatment of Mycoplasma bovis, one of the major pathogens responsible for bovine respiratory disease (BRD).
The new licence extension means that Zeleris is licenced for the treatment of BRD associated with pyrexia due to Mannheimia haemolytica, Pasteurella multocida, Histophilus somni AND Mycoplasma bovis. Mycoplasma bovis causes several diseases in cattle including respiratory disease in calves and arthritis, mastitis and pneumonia in older animals, generally in association with other pathogens.
Zeleris is an antibiotic and NSAID and features the unique combination of florfenicol and meloxicam, in one convenient injection. It is ideally suited for the treatment of BRD in cattle from four weeks of age and features the NSAID of vet choice for BRD, meloxicam1, which has a duration of action of up to three days and provides anti-inflammatory, antipyretic, anti-exudative and analgesic effects2, optimising long term productivity of the animal and supporting good welfare. Florfenicol has a wide spectrum of activity against the major BRD bacteria, including Mycoplasma bovis, Mannheimia haemolytica, Pasteurella multocida and Histophilus somni. Florfenicol has a fast and sustained duration of action from three to seven days3 with good distribution into the lung tissue4. It has good efficiency compared to oxytets5 without the need to retreat. Moreover, florfenicol is not used in human health medicine and has minimal reported resistance6.
The dose rate of Zeleris of 1ml/10kg subcutaneous injection is easy for farmers (and vets) to remember and calculate, while the syringeability of Zeleris is proven to be four times faster than similar treatments, even on cold days7. Zeleris is supplied in a CLAS® shock-resistant vial8 making it well suited for farm conditions.
Harry Walby, ruminant veterinary advisor for Zeleris at Ceva Animal Health, comments: “Mycoplasma bovis is notoriously difficult to contain and is very rarely isolated alone; it is frequently found alongside other pathogens including Mannheimia haemolytica, Pasteurella multocida and Histophilus somni. In the absence of an effective commercial vaccine, antimicrobial therapy remains the main control measure9 and early administration of a NSAID/antibiotic combination treatment, such as Zeleris, can aid treatment response and reduce the fever that typically comes with BRD compared with using an antibiotic treatment alone.”
For further information on Zeleris, please contact your Ceva Animal Health territory manager.
References
- 80 10 minute online interviews with vets who spend at least 50% of their professional time treating cattle. Mo Gannon Associates. July 2021
- Zeleris 400mg/ml solution for injection for cattle SPC
- Varma K.J. 1994 Microbiology, pharmacokinetic disposition and safety of florfenicol in cattle in Proceedings International Symposium on Bovine Respiratory Disease. World Buiatrics Congress, Toulouse, 18-24
- Foster, D. M. et al 2016. Comparison of Active Drug Concentrations in the Pulmonary Epithelial Lining Fluid and Interstitial Fluid of Calves Injected with Enrofloxacin, Florfenicol, Ceftiofur, or Tulathromycin. PLoS ONE 11, e0149100
- Andrés-Lasheras S. et al 2019. Serotyping and antimicrobial resistance of Mannheimia haemolytica strains from European cattle with bovine respiratory disease. Research in Veterinary Science 124:10-12
- Jourquin et al, 2022 Randomized field trial comparing the efficacy of florfenicol and oxytetracycline in a natural outbreak of calf pneumonia using lung reaeration as a cure criterion
- Achard et al (2017) Comparison of the syringeability of a new fixed combination of florfenicol and meloxicam (Zeleris®) with florfenicol-based products commonly used in bovine respiratory disease (BRD).Poster 00093 presented at EBF
- Cavaroc P. J. et al. – Comparative breakage study of injectable anti-infectives vials under vertical drop test by free fall under standardized conditions. IPVS Congress, 2012, 100
- Bokma et al., 2020 Antimicrobial Susceptibility of Mycoplasma bovis Isolates from Veal, Dairy and Beef Herds
More from Ceva
